Cantor Remains a Buy on PolarityTE Inc (PTE)
In a report released today, Elemer Piros from Cantor maintained a Buy rating on PolarityTE Inc (PTE), with a price target of $65. The company’s shares opened today at $1.37.
We factored in the RECELL Device in our market analysis of SkinTE. RECELL, an autologous skin product prepared at the bedside (a cell suspension sprayed onto the wound), was tested both on partial-thickness (standalone) or full-thickness burn wounds. In the latter setting, before the product is applied, a skin graft is necessary to cover the wound first. In these instances, RECELL was compared to control treatment (skin graft). A 32% reduction in skin graft area was shown as the benefit. The SkinTE treatment, whether on partial- or full-thickness burns, does NOT require skin graft to be used in conjunction. In addition, RECELL was tested in a randomized clinical trial on wounds averaging 165cm2 in size (roughly the size of the latest iPhone), while Polarity presented case studies in which entire limbs or large parts of the torso were treated with SkinTE. RECELL is indicated for patients 18 years or older. Polarity treated patients as young as 2.
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -5.9% and a 45.4% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.